

**MICHAEL G. KAUFFMAN, MD, PHD**

Co-founder, Senior Clinical Advisor

Dr. Kauffman co-founded Karyopharm with Dr. Sharon Shacham in 2008 and served as our Chief Executive Officer from January 2011 to April 2021, as Chief Medical Officer from December 2012 to July 2019, and as a director since 2008. He is currently a Senior Clinical Advisor to the Company helping to guide additional clinical development for Karyopharm's robust pipeline of programs, with an increasing focus on solid tumor indications.

Prior to joining Karyopharm, Dr. Kauffman served as Chief Medical Officer at Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. in November 2009 where he was Chief Medical Officer and where he led the development of Kyprolis[®] (carfilzomib), a novel proteasome inhibitor which was approved by the FDA for the treatment of refractory myeloma in 2012.

Prior to joining Onyx, Dr. Kauffman was an operating partner at Bessemer Venture Partners where he led investments in biotechnology companies. Prior to that, he served as President and Chief Executive Officer at Epix Pharmaceuticals, Inc. and President and Chief Executive Officer of Predix Pharmaceuticals, Inc. Dr. Kauffman led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals in 2006, oversaw the discovery and development of four new clinical candidates, and led collaboration transactions with Amgen and GlaxoSmithKline.

From 2000 to 2002, Dr. Kauffman was Vice President, Clinical at Millennium Pharmaceuticals, Inc., where he led the Velcade[®] (bortezomib) development program. From 1997 to 2000, Dr. Kauffman served in senior leadership roles at Millennium Predictive Medicine, Inc., a subsidiary of Millennium Pharmaceuticals, where he led the discovery and development of novel molecular diagnostics for major cancers and led transactions with Becton-Dickenson and Bristol Myers Squibb. From 1995 to 1997, he held a number of senior positions at Biogen Idec, Inc., where he led the clinical development of anti-D40L antibodies in autoimmune and inflammatory diseases, and acted as the main medical advisor to the Biogen business development group. Dr. Kauffman currently serves on the board of directors of Infinity Pharmaceuticals, Inc., Kezar Life Sciences, Inc. and Verastem Inc., which are all public biopharmaceutical companies.

Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College, his Doctor of Medicine and Doctor of Philosophy from Johns Hopkins Medical School, and trained in internal medicine and rheumatology at Beth Israel (now Beth Israel Deaconess Medical Center) and Massachusetts General Hospitals. He is board certified in internal medicine.

**SHARON SHACHAM, PHD, MBA**

Co-Founder, Chief Scientific Officer

Dr. Shacham co-founded Karyopharm in 2008 and has served as our Chief Scientific Officer since December 2012. She was also President of Research and Development from December 2012 to April 2021. From 2010 to 2012, Dr. Shacham served as our Chief Scientific Officer and Head of Research and Development, and prior to that, as our President and Chief Executive Officer. Dr. Shacham has led our scientific progress since inception.

Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led the company's efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials.

Dr. Shacham holds a Bachelor of Science in Chemistry, a Doctor of Philosophy in Chemistry, and a Master of Business of Administration from Tel Aviv University.

**BRIAN AUSTAD, PHD**Senior Vice President, Pharmaceutical Sciences

Brian has been leading Karyopharm's Pharmaceutical Sciences Department since November 2013 where he has been responsible for all CMC operations and supply chain activities. He brings nearly 20 years of experience in process chemistry with a focus on developing novel medicines for unmet needs. He has expertise in natural product synthesis and natural product derivatives, CMC management, and optimizing API synthetic routes and formulations manufacturing.

Prior to Karyopharm Therapeutics, he served in senior leadership roles at Rondaxe Pharma and Infinity. Brian served in roles of increasing responsibility at Eisai Research Institute, culminating in his role as Scientist, Process Chemistry, where he was a core contributor in the development and manufacture of Halaven[®] (eribulin mesylate), a fully synthetic derivative of the highly complex marine natural product Halichondrin B, approved for the treatment of breast cancer and liposarcoma.

Brian received his Bachelor of Science degree in Chemistry from the University of Wisconsin-Eau Claire and his Doctor of Philosophy in Synthetic Organic Chemistry from the University of Wisconsin-Madison, studying under Professor Steven D. Burke.

**DAVID FRAWLEY, MBA**

Senior Vice President, GMSA and Customer Excellence and Operations

David joined Karyopharm in April 2021 and is responsible for Global Medical Scientific Affairs and Customer Excellence and Operations.

David has built a 20+ year career driving growth at a number of leading pharmaceutical companies in both US and international markets and across multiple therapeutic categories, including psychiatry, neurology, and respiratory health. His strategic leadership has helped create motivated and aspirational corporate cultures while also delivering strong financial results at companies including Sunovion, Forest Laboratories, and Pfizer. David has directed commercial operations in complex, matrix-based global organizations and has supported clinical teams by providing commercial guidance throughout the drug development process. David has deep experience in M&A, licensing, and managing global partnerships and has served in leadership roles across the US, Canada, EMEA, and Europe.

David received his Master of Business Administration degree from the University of Bradford in Bradford, West Yorkshire, UK, and his Bachelor of Science in Biochemistry from University of Southampton in Southampton, UK.

**RAN FRENKEL, RPH**EVP, Chief Development Officer

Ran joined Karyopharm in October 2014. He manages Karyopharm Europe GmbH, a subsidiary of Karyopharm, which provides the necessary corporate structure to support Karyopharm's expanded clinical and regulatory activities in Europe. As Chief Development Operations Officer, Ran is also responsible for the corporate global development operations across the entire portfolio. In this capacity, he also manages the clinical departments including Clinical Operations, Medical Writing, Data Management, and Data Analysis.

Ran has more than 20 years of experience in the international biopharmaceutical industry encompassing clinical, regulatory, business development and commercial operations activities. Prior to joining Karyopharm Europe GmbH, he held a number of senior management roles in Europe, Israel and the United States, most recently as Managing Director EMEA for Clinipace Worldwide, an international clinical research organization, where he was responsible for the overall management of the organization in Europe, the Middle East and Africa. Prior to joining Clinipace Worldwide, Ran established and managed the Israeli office of PFC Pharma Focus AG, which was acquired by Clinipace in 2011, and where he held the position of Managing Director at Actelion Pharmaceuticals with responsibility for all science and business affairs of the company in Israel.

A registered pharmacist, Ran serves on the advisory board of Musli Thyropeutics and holds a Bachelor of Science in Pharmacy from the Hebrew University of Jerusalem.

**IAN KARP, MBA**Senior Vice President, Investor and Public Relations

Ian joined Karyopharm in July 2018 and is responsible for leading the company's corporate communications activities, including corporate visibility, financial communications, and media and investor relations.

Prior to joining Karyopharm, Ian held several roles with increasing responsibility at Shire plc, culminating in his role as Vice President and Head of Global Investor Relations. In addition, Ian previously served as Shire's Head of Commercial Assessment and played a critical role in Shire's corporate acquisition strategy between 2012-2016 which resulted in acquisitions totaling more than \$40B, including ViroPharma, Dyax, and Baxalta.

Before joining Shire, Ian served as Senior Director for Global Marketing, Emerging Oncology Brands at MedImmune, an AstraZeneca company. In this role, Ian served as MedImmune's commercial lead for clinical and preclinical programs across 20+ cancer indications in both solid tumors and hematological malignancies. Prior to his time at MedImmune, Ian held positions at Johnson & Johnson's Centocor division as well as at Pharmacia (now part of Pfizer) in a variety of sales and marketing roles, including field reimbursement support for Pharmacia's cancer franchise.

Ian received a Bachelor of Science degree in biology from Emory University and an MBA from Rutgers Business School with a concentration in pharmaceutical management.

**YOSEF LANDESMAN, PHD**Senior Vice President, Research and Translational Medicine

Dr. Landesman joined Karyopharm in 2011, where he began as Director, Head of Biology and currently serves as the Senior Vice President of Research and Translational Medicine. In this role, he leads Preclinical and Clinical Research, Karyopharm's Expanded Access Program, as well as the departments of Translational Development, Preclinical Pharmacology, Bioinformatics, and Clinical and Preclinical Publications. During his time at Karyopharm, Dr. Landesman has expanded on his broad experience in oncology at virtually every stage of drug development: from early discovery through clinical trial and approval. He led the preclinical development of XPOVIO[®] (selinexor) and initiated discovery of the Pak4/NAMPT dual inhibitor KPT-9274, currently in a Phase 1 clinical trial.

Prior to joining Karyopharm, Dr. Landesman worked at Alnylam Pharmaceuticals where he had a critical role in the establishment of the "RNAi Lead Development" department. In this multi-faceted position, he developed and optimized an efficient and simple method to quantify the delivery of siRNA and significantly contributed to the development of ONPATTRO[®] (patisiran). In addition, he was instrumental in a technology transfer agreement between Alnylam and Takeda Pharmaceuticals. He began his career as a scientist at GPC Biotech where he developed CDK small drug inhibitors and had a leadership role in the collaboration between GPC Biotech and the ALTANA Research Institute.

Dr. Landesman received his Bachelor and Master of Science degrees in Genetics from the Hebrew University of Jerusalem. He went on to earn his Doctor of Philosophy in Molecular Genetics and Virology from the Weizmann Institute of Science and completed his postdoctoral training at Harvard Medical School where he was also a faculty member of the Neurology Department.

**MIKE MANO, JD**Senior Vice President and General Counsel

Mike joined Karyopharm in December 2020 as Senior Vice President, General Counsel. He has over 15 years of legal experience and is responsible for leading all legal activities, including corporate law, SEC reporting, capital markets and financial transactions, strategic collaborations, litigation, contracts, corporate governances, human resources activities and general legal support of all other business activities. Prior to joining Karyopharm, Mike served as Counsel, Business Development for Biogen Inc. from January 2018 to December 2020, where he supported Biogen's global business development platform. Prior to that he was Senior Counsel at Proskauer Rose LLP, where he represented clients in a broad range of corporate matters. Mike received a Bachelor of Arts in Political Science and Sociology from Washington University and a Juris Doctor from Washington University School of Law.

**MICHAEL MASON, MBA, CPA**

Chief Financial Officer

Mike joined Karyopharm in February 2019 and is responsible for leading and directing the financial activities of the Company. He has over 18 years of diversified financial experience in executing financial strategies and leading growth initiatives for life sciences companies. He has deep expertise in global financial operations and controls, financing transactions, business planning and supporting pharmaceutical product launches.

Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG LLP, a national audit, tax and advisory services firm.

Mike received a Bachelor of Business Administration from Stetson University and an MBA from Babson College. He is also a Certified Public Accountant.

**LISA MELETTA, JD**Vice President, Legal & Chief Compliance Officer

Lisa joined Karyopharm in March 2021 as Vice President, Legal & Chief Compliance Officer.

Lisa has a deep healthcare law background including diversity of experience in law firm, government, and corporate settings. She has advised businesses through several new product launches as well as regulatory and litigation challenges, serving as a trusted partner to find compliant solutions to business needs.

Prior to joining Karyopharm, Lisa held legal roles of increasing responsibility within pharmaceutical companies, including Deputy General Counsel and Chief Compliance Officer. Her prior experience includes work at AMAG Pharmaceuticals, Novo Nordisk, and AVROBIO. Lisa began her legal career in the Washington, D.C. law firms of Ropes & Gray and Sidley Austin, defending pharmaceutical and medical device companies and their executives in healthcare fraud investigations and litigation.

Lisa's extensive healthcare law experience also includes serving as Assistant United States Attorney at the U.S. Department of Justice, where she worked closely with HHS-OIG, FBI, and other government agencies to prevent fraud.

Lisa earned her J.D. from New York University School of Law. Lisa graduated from New Jersey Institute of Technology with a B.S. in Management and pursued a career in marketing prior to law school.

**RONIT MILSTEIN, MBA**Vice President, Operations

Ronit joined Karyopharm February in 2014 and manages most of the administrative aspects of the business. Ronit brings over 20 years of management experience and comes to Karyopharm from Comverse Technology, Inc. where she was responsible for managing their research and development customization group. Ronit holds a Master of Business Administration from Heriot-Watt University and a Bachelor of Arts in Linguistics from the Hebrew University of Jerusalem.

**STEPHEN MITCHENER, PHARM D**Chief Business Officer

Stephen Mitchener joined Karyopharm in December 2020 and is responsible for setting the partnering and business strategy for the development and commercialization of all Karyopharm clinical and commercial programs.

Prior to joining Karyopharm, Steven served as Chief Business Officer and Head, Strategic Finance, and spearheaded all commercial, financing, partnering, and corporate development initiatives at Axcella Healthcare. Before joining Axcella Healthcare in 2018, Dr. Mitchener spent 15 years at Novartis in roles of increasing responsibility, in both U.S. and international roles within its Oncology Business. As Head of Strategy, Partnering and Operations, Dr. Mitchener was responsible for leading U.S. oncology strategy, enterprise operations, non-core brands and partnering activities. During his tenure at Novartis, he also held various commercial, medical and business development roles, including Business Franchise Head, Oncology, Global Pharma Strategy Director, and Global New Product Director. Dr. Mitchener was involved in securing partnerships in oncology with multiple Big Pharma, technology, academic and healthcare partners. Stephen has over seventeen years of partnering and corporate development experience within the biopharmaceutical industry.

Stephen received a PharmD from the University of North Carolina at Chapel Hill.

**ANAT HAAS MIZRAHI, LLB**

Senior Vice President, Legal Affairs and General Manager, Karyopharm Israel

Anat is responsible for leading Karyopharm's Israeli organization, which manages much of the Company's ex-US operations. She joined Karyopharm in 2009, initially serving in leadership roles within the Company's legal department, including as Head of the Contracts Department, and held a variety of roles with increasing responsibility within Karyopharm's Clinical Operations organization.

Before joining Karyopharm, Anat served as Counsel – Corporate Contracts for Epix Pharmaceuticals Inc. leading Epix R&D and clinical contracts activities. Prior to joining the biotechnology industry, Anat worked as legal counsel and litigator at Zeev Weil and Co., a law firm based in Jerusalem, Israel, specializing in Civil Law, Tort Law, Medical Negligence and Malpractice.

Anat is a member of the Israeli Bar (since 1999) and the New York Bar (since 2007) and received her law degree from "Sha'arei Mishpat" College in Israel.

**STEVEN ROTMAN, MSC**

Chief People and Corporate Engagement Officer

Steven Rotman joined Karyopharm in October 2019 and is responsible for leading the Human Resources function, with a focus on people and culture.

Steven has over twenty years' experience in the field of Human Resources, spanning multiple industries including Healthcare, Software, and Professional Services. Before joining Karyopharm, Steven was the Chief People Officer at Ipswitch, Inc. where he helped the Company earn numerous "Top Places To Work" honors and played an integral role in the Company's successful sale to Progress Software. Prior to Ipswitch, Steven worked in the Healthcare IT space for over ten years as the Vice President of Human Resources at NaviNet, a leading healthcare technology company. Under Steven's leadership, NaviNet was recognized with numerous "Best-In-Class" employer accolades before NaviNet's acquisition by NantHealth in 2016. Steven's focus has always been on aligning the business needs of an organization with the critical human capital needed to be successful, aiming for a winning culture. Steven has helped multiple organizations grow both organically and via M&A activity, including helping them to expand their corporate footprint to multiple, global locations.

Steven earned his B.A. in Interpersonal Communication and Political Science at the University of New Hampshire and holds a Master's Degree in Human Resources from Suffolk University. Steven has been a board advisor to the "Best & Brightest Companies" for both the Boston and the National programs since 2017.

**JATIN SHAH, MD**Executive Vice President, Chief Medical Officer

As Karyopharm's Executive Vice President, Chief Medical Officer, Dr. Jatin Shah is responsible for overseeing the company's ongoing clinical programs.

Dr. Shah brings significant medical oncology experience to Karyopharm from his prior work at The University of Texas MD Anderson Cancer Center (MD Anderson), including work as a treating physician for patients with multiple myeloma and clinical research. For nearly ten years at MD Anderson, Dr. Shah served as an Associate Professor and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine.

Dr. Shah received his medical degree from Ohio State University College of Medicine, Columbus, Ohio, and his undergraduate degree, also from Ohio State University, in Mechanical Engineering. He completed an internship and residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah holds board certification in hematology and oncology from the American Board of Internal Medicine. He has served as principal investigator/co-investigator for numerous relapsed/refractory multiple myeloma studies and has published articles and abstracts in many peer-reviewed journals.

**RICHARD PAULSON, MBA**President and Chief Executive Officer

Mr. Paulson was appointed President and Chief Executive Officer of Karyopharm in May 2021 and has served as a member of Karyopharm's Board of Directors since February 2020. He was previously an Executive Vice President of Ipsen Pharmaceuticals, Inc. and Chief Executive Officer of Ipsen North America, a global biopharmaceutical company focused on innovation and specialty care in areas of oncology, neuroscience and rare diseases, from February 2018 to May 2021. Mr. Paulson previously worked at Amgen for 10 years holding varying leadership positions across Europe and North America, including Vice President and General Manager of Amgen's U.S. Oncology Business Unit, and prior to that served as the Vice President of Marketing for Amgen's U.S. Oncology Business, General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to Amgen, Mr. Paulson held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic. Mr. Paulson also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada.

Mr. Paulson has an MBA from the University of Toronto, Canada and an undergraduate degree in commerce from the University of Saskatchewan, Canada.

**SOHANYA CHENG, MBA**

Senior Vice President of Sales and Commercial Operations

Sohanya Cheng joined Karyopharm in June 2021 and is responsible for leading the company's Sales and Commercial Operations functions.

Sohanya brings 17 years of biopharmaceutical commercialization and research experience to Karyopharm, predominately in the oncology space. Prior to joining Karyopharm, Sohanya served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals and prior to this role, spent over 10 years within the commercial organization at Amgen. While at Amgen, Sohanya held a variety of sales and marketing leadership roles supporting the commercialization of key oncology brands, including Kyprolis[®] for multiple myeloma and Blincyto[®] for acute lymphoblastic lymphoma, and served as Amgen's Executive Director, Head of Marketing & Sales for their multiple myeloma business.

Sohanya holds an MBA from the MIT Sloan School of Management and a BSc and MA from the University of Cambridge, UK.

**PAYMAN DAROUIAN, PHARM D**Senior Vice President of Marketing

Payman Darouian joined Karyopharm in January 2021 and is responsible for all marketing efforts for XPOVIO.

Prior to joining Karyopharm, he spent more than 17 years in a variety of commercial leadership roles, predominately in the oncology space, including at Novartis where Payman served as the Executive Director and Global Brand Lead for Targeted Lung Cancer Therapies and also led commercial strategy for their Solid Tumor and Immuno-Oncology business. Prior to Novartis, Payman helped lead worldwide commercialization of Opdivo[®] for the treatment of head and neck cancer at Bristol Myers Squibb. Finally, while at Sanofi, Payman held numerous marketing leadership roles over an eight year period supporting key oncology brands, including Jevtana[®] and Eloxatin[®].

Payman holds a PharmD from the Albany College of Pharmacy and a BS from the University of Massachusetts, Amherst.